IBDEI1EX ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,25328,1,4,0)
 ;;=4^V16.8
 ;;^UTILITY(U,$J,358.3,25328,1,5,0)
 ;;=5^Family h/o Cancer,Other Specified
 ;;^UTILITY(U,$J,358.3,25328,2)
 ;;=^295300
 ;;^UTILITY(U,$J,358.3,25329,0)
 ;;=V11.1^^145^1538^24
 ;;^UTILITY(U,$J,358.3,25329,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25329,1,4,0)
 ;;=4^V11.1
 ;;^UTILITY(U,$J,358.3,25329,1,5,0)
 ;;=5^Hx of Affective Disorder
 ;;^UTILITY(U,$J,358.3,25329,2)
 ;;=^295250
 ;;^UTILITY(U,$J,358.3,25330,0)
 ;;=V15.89^^145^1538^46
 ;;^UTILITY(U,$J,358.3,25330,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25330,1,4,0)
 ;;=4^V15.89
 ;;^UTILITY(U,$J,358.3,25330,1,5,0)
 ;;=5^Hx of Persian Gulf Region Exposure
 ;;^UTILITY(U,$J,358.3,25330,2)
 ;;=^295291
 ;;^UTILITY(U,$J,358.3,25331,0)
 ;;=V11.3^^145^1538^25
 ;;^UTILITY(U,$J,358.3,25331,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25331,1,4,0)
 ;;=4^V11.3
 ;;^UTILITY(U,$J,358.3,25331,1,5,0)
 ;;=5^Hx of Alcoholism
 ;;^UTILITY(U,$J,358.3,25331,2)
 ;;=^295252
 ;;^UTILITY(U,$J,358.3,25332,0)
 ;;=V15.07^^145^1538^26
 ;;^UTILITY(U,$J,358.3,25332,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25332,1,4,0)
 ;;=4^V15.07
 ;;^UTILITY(U,$J,358.3,25332,1,5,0)
 ;;=5^Hx of Allergy to Latex
 ;;^UTILITY(U,$J,358.3,25332,2)
 ;;=^322043
 ;;^UTILITY(U,$J,358.3,25333,0)
 ;;=V13.4^^145^1538^27
 ;;^UTILITY(U,$J,358.3,25333,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25333,1,4,0)
 ;;=4^V13.4
 ;;^UTILITY(U,$J,358.3,25333,1,5,0)
 ;;=5^Hx of Arthritis
 ;;^UTILITY(U,$J,358.3,25333,2)
 ;;=^295267
 ;;^UTILITY(U,$J,358.3,25334,0)
 ;;=V12.72^^145^1538^31
 ;;^UTILITY(U,$J,358.3,25334,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25334,1,4,0)
 ;;=4^V12.72
 ;;^UTILITY(U,$J,358.3,25334,1,5,0)
 ;;=5^Hx of Colon Polyps
 ;;^UTILITY(U,$J,358.3,25334,2)
 ;;=^303401
 ;;^UTILITY(U,$J,358.3,25335,0)
 ;;=V12.59^^145^1538^30
 ;;^UTILITY(U,$J,358.3,25335,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25335,1,4,0)
 ;;=4^V12.59
 ;;^UTILITY(U,$J,358.3,25335,1,5,0)
 ;;=5^Hx of CHF
 ;;^UTILITY(U,$J,358.3,25335,2)
 ;;=^303399
 ;;^UTILITY(U,$J,358.3,25336,0)
 ;;=V45.81^^145^1538^29
 ;;^UTILITY(U,$J,358.3,25336,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25336,1,4,0)
 ;;=4^V45.81
 ;;^UTILITY(U,$J,358.3,25336,1,5,0)
 ;;=5^Hx of CABG
 ;;^UTILITY(U,$J,358.3,25336,2)
 ;;=^97129
 ;;^UTILITY(U,$J,358.3,25337,0)
 ;;=V15.84^^145^1538^28
 ;;^UTILITY(U,$J,358.3,25337,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25337,1,4,0)
 ;;=4^V15.84
 ;;^UTILITY(U,$J,358.3,25337,1,5,0)
 ;;=5^Hx of Asbestos Exposure
 ;;^UTILITY(U,$J,358.3,25337,2)
 ;;=^303406
 ;;^UTILITY(U,$J,358.3,25338,0)
 ;;=V15.85^^145^1538^47
 ;;^UTILITY(U,$J,358.3,25338,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25338,1,4,0)
 ;;=4^V15.85
 ;;^UTILITY(U,$J,358.3,25338,1,5,0)
 ;;=5^Hx of Potentially Hazardous Body Fluids
 ;;^UTILITY(U,$J,358.3,25338,2)
 ;;=^303407
 ;;^UTILITY(U,$J,358.3,25339,0)
 ;;=V10.72^^145^1538^34
 ;;^UTILITY(U,$J,358.3,25339,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25339,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,25339,1,5,0)
 ;;=5^Hx of Hodgkin's Disease
 ;;^UTILITY(U,$J,358.3,25339,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,25340,0)
 ;;=V15.3^^145^1538^35
 ;;^UTILITY(U,$J,358.3,25340,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25340,1,4,0)
 ;;=4^V15.3
 ;;^UTILITY(U,$J,358.3,25340,1,5,0)
 ;;=5^Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,25340,2)
 ;;=^295285
 ;;^UTILITY(U,$J,358.3,25341,0)
 ;;=V10.61^^145^1538^37
 ;;^UTILITY(U,$J,358.3,25341,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,25341,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,25341,1,5,0)
 ;;=5^Hx of Lymphoid Leukemia
 ;;^UTILITY(U,$J,358.3,25341,2)
 ;;=Hx of Lymphoid Leukemia^295232
